{"schema_version":"1.0","type":"article","title":"Old Targets Are Crowded, but They Can Still Make Money","url":"https://drugnews.com.tw/articles/2026-06-06-old-targets-differentiation-strategy-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-06-old-targets-differentiation-strategy-en.md","lang":"en","date":"2026-06-06","publish_at":"2026-06-06T10:30:00+08:00","updated_at":"2026-06-06","category":"商業分析系列","topic":"BD / 授權","tags":["BD and Licensing","Business development","Biotech business analysis","Drug development"],"summary":"Crowded drug targets can still create value when companies differentiate through patient selection, formulation, route of administration, clinical design, pricing, or commercial channel strategy.","key_points":[],"facts":[],"sections":["Core Thesis","Why It Matters","Reading Framework","What To Watch Next","Original Chinese Edition"],"references":[],"images":[],"cover_image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-06）。Old Targets Are Crowded, but They Can Still Make Money。https://drugnews.com.tw/articles/2026-06-06-old-targets-differentiation-strategy-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-06-06-old-targets-differentiation-strategy.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}